Flange
发表于 2025-3-21 19:34:00
书目名称Immune Modulation and Anti-Inflammatory Therapy in Ocular Disorders影响因子(影响力)<br> http://figure.impactfactor.cn/if/?ISSN=BK0462055<br><br> <br><br>书目名称Immune Modulation and Anti-Inflammatory Therapy in Ocular Disorders影响因子(影响力)学科排名<br> http://figure.impactfactor.cn/ifr/?ISSN=BK0462055<br><br> <br><br>书目名称Immune Modulation and Anti-Inflammatory Therapy in Ocular Disorders网络公开度<br> http://figure.impactfactor.cn/at/?ISSN=BK0462055<br><br> <br><br>书目名称Immune Modulation and Anti-Inflammatory Therapy in Ocular Disorders网络公开度学科排名<br> http://figure.impactfactor.cn/atr/?ISSN=BK0462055<br><br> <br><br>书目名称Immune Modulation and Anti-Inflammatory Therapy in Ocular Disorders被引频次<br> http://figure.impactfactor.cn/tc/?ISSN=BK0462055<br><br> <br><br>书目名称Immune Modulation and Anti-Inflammatory Therapy in Ocular Disorders被引频次学科排名<br> http://figure.impactfactor.cn/tcr/?ISSN=BK0462055<br><br> <br><br>书目名称Immune Modulation and Anti-Inflammatory Therapy in Ocular Disorders年度引用<br> http://figure.impactfactor.cn/ii/?ISSN=BK0462055<br><br> <br><br>书目名称Immune Modulation and Anti-Inflammatory Therapy in Ocular Disorders年度引用学科排名<br> http://figure.impactfactor.cn/iir/?ISSN=BK0462055<br><br> <br><br>书目名称Immune Modulation and Anti-Inflammatory Therapy in Ocular Disorders读者反馈<br> http://figure.impactfactor.cn/5y/?ISSN=BK0462055<br><br> <br><br>书目名称Immune Modulation and Anti-Inflammatory Therapy in Ocular Disorders读者反馈学科排名<br> http://figure.impactfactor.cn/5yr/?ISSN=BK0462055<br><br> <br><br>
蛤肉
发表于 2025-3-22 00:05:27
http://reply.papertrans.cn/47/4621/462055/462055_2.png
altruism
发表于 2025-3-22 00:29:37
http://reply.papertrans.cn/47/4621/462055/462055_3.png
演讲
发表于 2025-3-22 08:04:30
http://reply.papertrans.cn/47/4621/462055/462055_4.png
有节制
发表于 2025-3-22 11:35:48
Cystoid Macular Edema,patients is estimated between 20 and 30 % and is a major cause of permanent vision loss . About 35 % of uveitis patients with a vision less than 0.1 (6/60) have macular edema, though its prevalence as a cause of poor vision varies with the duration of uveitis. It is reported in 17 % of cases at year 1 and increases to 30 % by year 5 .
光亮
发表于 2025-3-22 13:19:08
978-3-662-50738-4The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer-Verlag GmbH, DE
BARK
发表于 2025-3-22 20:46:35
http://reply.papertrans.cn/47/4621/462055/462055_7.png
Scleroderma
发表于 2025-3-22 21:41:47
Treatment of Inflammation Secondary to Vitreoretinal Surgery,Vitreoretinal surgery is comprised of a number of techniques, and any of them can cause inflammation for different reasons. This chapter will focus on the treatment of inflammation caused by scleral buckling, pars plana vitrectomy, and combined procedure phacovitrectomy.
Crepitus
发表于 2025-3-23 04:51:50
http://reply.papertrans.cn/47/4621/462055/462055_9.png
lobster
发表于 2025-3-23 08:02:42
Diagnosis and Management of Scleritis,cond-line immunosuppressive agents. Subconjunctival corticosteroid injection may be an option in non-necrotising noninfectious anterior scleritis, particularly in those who fail to respond to initial systemic therapy. Biologic agents, particularly infliximab and rituximab, may prove useful in refrac